EBS Emergent BioSolutions Inc
Price (delayed)
$5.17
Market cap
$280.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.6
Enterprise value
$839.02M
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated
Highlights
EBS's EPS has soared by 76% year-on-year and by 8% since the previous quarter
The net income has soared by 75% YoY and by 9% from the previous quarter
EBS's gross profit is up by 5% year-on-year but it is down by 3.9% since the previous quarter
EBS's equity is down by 26% year-on-year and by 5% since the previous quarter
The company's revenue fell by 7% QoQ
Key stats
What are the main financial stats of EBS
Market
Valuations
Earnings
Shares outstanding
54.34M
Market cap
$280.92M
Enterprise value
$839.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
0.26
EV/EBIT
N/A
EV/EBITDA
22.74
EV/Sales
0.8
Revenue
$1.04B
Gross profit
$362.3M
Operating income
-$108.7M
Net income
-$190.6M
EBIT
-$71.9M
EBITDA
$36.9M
Free cash flow
$43.7M
Per share
Balance sheet
Liquidity
EPS
-$3.6
EPS diluted
-$3.6
Free cash flow per share
$0.82
Book value per share
$8.91
Revenue per share
$19.69
TBVPS
$16.76
Total assets
$1.39B
Total liabilities
$906.9M
Debt
$663.7M
Equity
$482.8M
Working capital
$436.3M
Debt to equity
1.37
Current ratio
3.69
Quick ratio
1.6
Net debt/EBITDA
15.12
Margins
Efficiency
Dividend
EBITDA margin
3.5%
Gross margin
34.7%
Net margin
-18.3%
Operating margin
-10.4%
Return on assets
-12.3%
Return on equity
-37.3%
Return on invested capital
-5.6%
Return on capital employed
-5.9%
Return on sales
-6.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBS stock price
How has the Emergent BioSolutions stock price performed over time
Intraday
9.07%
1 week
0%
1 month
-30.88%
1 year
139.35%
YTD
-45.92%
QTD
6.38%
Financial performance
How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$362.3M
Operating income
-$108.7M
Net income
-$190.6M
Gross margin
34.7%
Net margin
-18.3%
The company's operating margin has surged by 85% YoY and by 18% QoQ
EBS's operating income has soared by 85% YoY and by 24% from the previous quarter
The net income has soared by 75% YoY and by 9% from the previous quarter
Emergent BioSolutions's net margin has surged by 75% YoY
Growth
What is Emergent BioSolutions's growth rate over time
Valuation
What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.58
P/S
0.26
EV/EBIT
N/A
EV/EBITDA
22.74
EV/Sales
0.8
EBS's EPS has soared by 76% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 65% lower than the 5-year quarterly average of 1.5 and 34% lower than the last 4 quarters average of 0.8
EBS's equity is down by 26% year-on-year and by 5% since the previous quarter
The P/S is 82% below the 5-year quarterly average of 1.3 and 20% below the last 4 quarters average of 0.3
The company's revenue fell by 7% QoQ
Efficiency
How efficient is Emergent BioSolutions business performance
EBS's ROS has soared by 89% year-on-year and by 16% since the previous quarter
EBS's ROIC has soared by 87% YoY and by 21% QoQ
The company's return on assets has surged by 64% YoY and by 2.4% QoQ
EBS's return on equity has surged by 57% year-on-year
Dividends
What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBS.
Financial health
How did Emergent BioSolutions financials performed over time
The total assets is 53% more than the total liabilities
EBS's quick ratio is up by 32% QoQ
Emergent BioSolutions's current ratio has increased by 28% from the previous quarter
Emergent BioSolutions's debt is 37% higher than its equity
EBS's equity is down by 26% year-on-year and by 5% since the previous quarter
Emergent BioSolutions's debt has decreased by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.